OBR News Hub – OBR
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.
Related Articles
Breast Cancer: New Horizons, Current Controversies
Breast Cancer: New Horizons, Current Controversies is a comprehensive educational curriculum that encompasses the full range of breast cancer care. Topics include mechanisms of disease,…
Breast Cancer: New Horizons, Current Controversies
Breast Cancer: New Horizons, Current Controversies is a comprehensive educational curriculum that encompasses the full range of breast cancer care. Topics include mechanisms of disease,…
Support Kancer Killers – Pickleball for a Purpose 2025
We’re excited to join this incredible initiative! This organization’s mission is very important to us and we’re proud to help them make a difference. Please…
Imfinzi regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
Positive high-level results from the POTOMAC Phase III trial showed one year of t reatment with AstraZeneca’s Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance…
Development of a FKSI-23: A new bespoke health-related quality of life (HRQOL) questionnaire for the advanced and adjuvant setting in renal cell carcinoma (RCC).
526Background: Existing HRQOL measures may not fully capture the experiences of patients with localized and advanced RCC. This study aimed to develop a validated, patient-centered…
Immunotherapy before and after surgery improves outcomes in head and neck cancer | Dana-Farber Cancer Institute
Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival…
FDA Approves Nivolumab/Ipilimumab in First-Line Hepatocellular Cancer
Findings from the CheckMate 9DW trial support the FDA approval of nivolumab and ipilimumab in unresectable hepatocellular carcinoma
What you need to know as the May 7 Real ID deadline approaches
Driver’s licenses and IDs that are not Real ID-compliant will no longer get you through U.S. airport security once the law takes effect in a…
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation
Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and…